Celldex Therapeutics, Inc. (CLDX)
39.42
+0.18
(+0.46%)
USD |
NASDAQ |
Sep 02, 10:41
Celldex Therapeutics PS Ratio : 17297.08 for Sept. 2, 2026
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| September 01, 2026 | 17218.10 |
| August 31, 2026 | 17389.23 |
| August 28, 2026 | 17165.45 |
| August 27, 2026 | 17753.43 |
| August 26, 2026 | 17801.69 |
| August 25, 2026 | 18086.91 |
| August 24, 2026 | 17801.69 |
| August 21, 2026 | 17718.32 |
| August 20, 2026 | 17525.25 |
| August 19, 2026 | 18297.52 |
| August 18, 2026 | 18337.02 |
| August 17, 2026 | 18394.06 |
| August 14, 2026 | 18407.22 |
| August 13, 2026 | 18696.82 |
| August 12, 2026 | 19688.49 |
| August 11, 2026 | 19451.54 |
| August 10, 2026 | 18854.79 |
| August 07, 2026 | 18301.91 |
| August 06, 2026 | 18236.09 |
| August 05, 2026 | 18016.70 |
| August 04, 2026 | 17134.73 |
| August 03, 2026 | 16537.98 |
| July 31, 2026 | 16700.33 |
| July 30, 2026 | 16886.82 |
| July 29, 2026 | 16459.00 |
| Date | Value |
|---|---|
| July 28, 2026 | 15612.13 |
| July 27, 2026 | 15642.85 |
| July 24, 2026 | 15480.50 |
| July 23, 2026 | 15541.93 |
| July 22, 2026 | 15256.71 |
| July 21, 2026 | 15647.24 |
| July 20, 2026 | 15541.93 |
| July 17, 2026 | 15511.21 |
| July 16, 2026 | 15533.15 |
| July 15, 2026 | 16810.03 |
| July 14, 2026 | 16748.60 |
| July 13, 2026 | 16906.56 |
| July 10, 2026 | 17161.06 |
| July 09, 2026 | 17104.02 |
| July 08, 2026 | 17095.24 |
| July 07, 2026 | 17520.87 |
| July 06, 2026 | 16652.06 |
| July 02, 2026 | 16836.36 |
| July 01, 2026 | 16138.68 |
| June 30, 2026 | 16327.36 |
| June 29, 2026 | 2873.57 |
| June 26, 2026 | 2706.26 |
| June 25, 2026 | 2616.46 |
| June 24, 2026 | 2592.66 |
| June 23, 2026 | 2531.26 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Gilead Sciences, Inc. | 6.142 |
| Ionis Pharmaceuticals, Inc. | 11.18 |
| ACADIA Pharmaceuticals, Inc. | 4.402 |
| Alnylam Pharmaceuticals, Inc. | 7.290 |
| Anika Therapeutics, Inc. | 2.488 |
PS Ratio Related Metrics
| PEG Ratio | -0.2014 |
| Price to Book Value | 4.331 |
| Price | 39.42 |
| Earnings Yield | -11.06% |
| Market Cap | 3.094B |
| PEGY Ratio | -0.2014 |